Valid MeSH ConditionsHTN-MortNCT07067632
Mortality Outcome of Controlled Blood Pressure Participants
An observational study of Valid MeSH Conditions and Hypertension (HTN), run by DejthidaNathaphong at 1 site in Thailand.
Trial summary
Despite advances in antihypertensive therapy, some patients with well-controlled blood pressure still experience fatal outcomes. This paradox raises critical questions about the efficacy of blood pressure-targeted interventions and whether BP control alone ensures survival. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Valid MeSH Conditions, Hypertension (HTN)
- What is being tested?
- Antihypertensive treatment
- How many people
- 246,587 participants
- Where
- 1 siteThailand
- Study dates
- 1 Jul 2025to 29 Sep 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults ≥18 years with diagnosed hypertension Blood pressure controlled at target values defined by the study (e.g., <140/90 mmHg or <130/80 mmHg) Any comorbidity allowed unless the study focuses on pregnancy or pediatric population
Who may be able to join
- Adults ≥18 years with diagnosed hypertension
- Blood pressure controlled at target values defined by the study (e.g., <140/90 mmHg or <130/80 mmHg)
- Any comorbidity allowed unless the study focuses on pregnancy or pediatric population
Who cannot join
- Observational or retrospective studies
- Pediatric or pregnant participants
- Case reports, editorials, or conference abstracts without full data
- Studies not reporting mortality outcomes separately for controlled BP
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Mortality Outcome of Controlled Hypertension in Randomized Controlled or Open-label Study Intentionally Directed Intervention Effect Blood Pressure: A Systematic Review and Meta-Analysis
Despite advances in antihypertensive therapy, some patients with well-controlled blood pressure still experience fatal outcomes. This paradox raises critical questions about the efficacy of blood pressure-targeted interventions and whether BP control alone ensures survival. This systematic review and meta-analysis aims to evaluate all-cause mortality and cardiovascular death among hypertensive patients who achieved BP targets in RCTs or open-label trials.
To determine whether achieving controlled blood pressure through intentional intervention (pharmacological or procedural) in RCTs or open-label studies reduces mortality (all-cause and cardiovascular) in hypertensive patients.
Read the detailed description
Sensitivity Analyses Excluding high-risk of bias studies Excluding short follow-up (<1 year)
- Conditions
- Valid MeSH Conditions, Hypertension (HTN)
- Being tested
- Antihypertensive treatment
- Keywords
- hypertension, cardiovascular death
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antihypertensive treatmentDrug
Also called device-based blood pressure lowering, lifestyle modification
Any intervention (pharmacological, device-based, lifestyle) intentionally directed at lowering BP
Control groups receiving placebo, standard of care, or no intervention
| Study group | Role | What they receive |
|---|---|---|
| Antihypertensive treatment | Participants assigned to interventions (pharmacological, device-based, or lifestyle) directed at lowering blood pressure or Antihypertensive agents, Blood pressure-lowering treatment, Antihypertensive therapy. Receives: Drug: Antihypertensive treatment | |
| Control/Comparator | Participants receiving placebo, standard of care, or no intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
All-cause mortality
All cause mortality by controlable hypertension treatment
Measured: 100 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2025
- Study start1 Jul 2025
- Primary completion29 Sep 2026
- Study completion29 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Valid MeSH ConditionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 246,587 participants (actual)
Sponsor and investigators
- Lead sponsor
- DejthidaNathaphong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nathaphong Dejthida, DejthidaNathaphong
- Investigators
- Nathaphong Dejthida, MD, Principal investigator, DejthidaNathaphong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07067632
- Sponsor's protocol ID
- DejthidaNathaphong
- Acronym
- HTN-Mort
- Status last verified
- Nov 2026
- First submitted
- 6 Jul 2025
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mortality Outcome of Controlled Hypertension in Randomized Controlled or Open-label Study Intentionally Directed Intervention Effect Blood Pressure: A Systematic Review and Meta-Analysis
- ClinicalTrials.gov ID
- NCT07067632
- Acronym / sponsor ID
- HTN-Mort / DejthidaNathaphong
- Conditions
- Valid MeSH Conditions, Hypertension (HTN)
- Keywords
- hypertension, cardiovascular death
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 246,587 participants (actual)
- Lead sponsor
- DejthidaNathaphongUniversity, hospital or other
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 29 Sep 2026 (actual)
- Study completion
- 29 Sep 2026 (actual)
- First posted
- 16 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite advances in antihypertensive therapy, some patients with well-controlled blood pressure still experience fatal outcomes. This paradox raises critical questions about the efficacy of blood pressure-targeted interventions and whether BP control alone ensures survival. This systematic review and meta-analysis aims to evaluate all-cause mortality and cardiovascular death among hypertensive patients who achieved BP targets in RCTs or open-label trials.
To determine whether achieving controlled blood pressure through intentional intervention (pharmacological or procedural) in RCTs or open-label studies reduces mortality (all-cause and cardiovascular) in hypertensive patients.
Detailed description
Sensitivity Analyses Excluding high-risk of bias studies Excluding short follow-up (<1 year)
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Antihypertensive treatment | – | Drug: Antihypertensive treatmentParticipants assigned to interventions (pharmacological, device-based, or lifestyle) directed at lowering blood pressure or Antihypertensive agents, Blood pressure-lowering treatment, Antihypertensive therapy. |
| Control/Comparator | – | –Participants receiving placebo, standard of care, or no intervention |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults ≥18 years with diagnosed hypertension Blood pressure controlled at target values defined by the study (e.g., <140/90 mmHg or <130/80 mmHg) Any comorbidity allowed unless the study focuses on pregnancy or pediatric population
Key inclusion criteria (3 listed)
- Adults ≥18 years with diagnosed hypertension
- Blood pressure controlled at target values defined by the study (e.g., <140/90 mmHg or <130/80 mmHg)
- Any comorbidity allowed unless the study focuses on pregnancy or pediatric population
Key exclusion criteria (4 listed)
- Observational or retrospective studies
- Pediatric or pregnant participants
- Case reports, editorials, or conference abstracts without full data
- Studies not reporting mortality outcomes separately for controlled BP
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antihypertensive treatmentAlso: device-based blood pressure lowering, lifestyle modificationAny intervention (pharmacological, device-based, lifestyle) intentionally directed at lowering BP Control groups receiving placebo, standard of care, or no intervention | Drug | Antihypertensive treatment |
Primary outcome
All-cause mortality
Time frame: 100 year
All cause mortality by controlable hypertension treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Individual participant dataSharing planned: Yes
Related trials for Valid MeSH Conditions
Not yet recruitingPhase 2
An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
Valid MeSH Conditions
RecruitingObservational study
"Menopause Experiences in Cultural and Intercultural Contexts"
Valid MeSH Conditions
Not yet recruitingObservational study
Textbook Outcomes in Urgent Appendectomy
Valid MeSH Conditions
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nathaphong Dejthida, MD principal investigator
DejthidaNathaphong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Valid MeSH Conditions and Hypertension (HTN), run by DejthidaNathaphong at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All-cause mortality (time frame: 100 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.